SIWA Therapeutics Email Format
Biotechnology ResearchIllinois, United States2-10 Employees
SIWA Therapeutics is a privately held biotechnology company based in Chicago, Illinois, that operates in the preclinical stage. It is developing a monoclonal antibody intended to identify and eliminate senescent cells, aiming to address diseases where these cells contribute to disease progression. Initial focus areas include rare conditions such as cancer metastasis and muscle-wasting diseases like muscular dystrophy, with broader implications for neurodegenerative and autoimmune diseases. The company is actively optimizing its lead antibody, SIWA 318, while seeking partnerships to advance SIWA 318 and related technologies and expand its development pipeline. With a small team, SIWA positions itself within the biotechnology research sector as a facilitator of collaboration to pursue therapies targeting cellular aging processes.